These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30915567)

  • 21. Ten-Year Trends in Antiemetic Prescribing in Patients Receiving Highly Emetogenic Chemotherapy.
    O'Sullivan CC; Van Houten HK; Sangaralingham LR; Leal AD; Shinde S; Liu H; Ettinger D; Loprinzi CL; Ruddy KJ
    J Natl Compr Canc Netw; 2018 Mar; 16(3):294-299. PubMed ID: 29523668
    [No Abstract]   [Full Text] [Related]  

  • 22. Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States.
    Schwartzberg L; Morrow G; Balu S; Craver C; Gayle J; Cox D
    Curr Med Res Opin; 2011 Aug; 27(8):1613-22. PubMed ID: 21696263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
    Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
    J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).
    Aapro M; Molassiotis A; Dicato M; Peláez I; Rodríguez-Lescure Á; Pastorelli D; Ma L; Burke T; Gu A; Gascon P; Roila F;
    Ann Oncol; 2012 Aug; 23(8):1986-1992. PubMed ID: 22396444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan.
    Baba Y; Baba H; Yamamoto S; Shimada H; Shibata T; Miyazaki T; Yoshikawa T; Nakajima Y; Tsuji Y; Shimokawa M; Kitagawa Y; Aiba K
    Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2017 Apr; 22(2):405-412. PubMed ID: 27909835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study.
    De Tursi M; Carella C; Tomao S; Cinieri S; Lorusso V; Marchetti P; Vecchio S; Sansoni E; Contu A; Adamo V; Silvestris N; Nuzzo A; Rosti G; Ravaioli A; Danova M; Tonini G; Passalacqua R; Cruciani G; Faedi M; Spada M; De Laurentiis M; Amoroso D; Tomao F; Sperduti I; Grassadonia A; Tinari N; Natoli C; Iacobelli S;
    Tumori; 2014; 100(6):e309-13. PubMed ID: 25688518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prescription trends of prophylactic antiemetics for chemotherapy-induced nausea and vomiting in Japan.
    Okuyama A; Nakamura F; Higashi T
    Support Care Cancer; 2014 Jul; 22(7):1789-95. PubMed ID: 24522743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
    Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
    J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
    Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
    Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world effectiveness of palonosetron-based antiemetic regimens: preventing chemotherapy-induced nausea and vomiting.
    Schwartzberg LS; Marks SM; Gabrail NY; Geller RB; Kish J
    J Comp Eff Res; 2019 Jul; 8(9):657-670. PubMed ID: 31070042
    [No Abstract]   [Full Text] [Related]  

  • 33. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting.
    Burke TA; Wisniewski T; Ernst FR
    Support Care Cancer; 2011 Jan; 19(1):131-40. PubMed ID: 20101417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The compliance with antiemetic guidelines of Turkish medical oncologists. A survey study of Turkish Oncology Group.
    Araz M; Karaagac M; Korkmaz L; Beypinar I; Uysal M
    Curr Probl Cancer; 2019 Aug; 43(4):344-353. PubMed ID: 30497851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy.
    Roeland EJ; Ruddy KJ; LeBlanc TW; Nipp RD; Binder G; Sebastiani S; Potluri R; Schmerold L; Papademetriou E; Schwartzberg L; Navari RM
    J Natl Compr Canc Netw; 2020 Jun; 18(6):676-681. PubMed ID: 32502985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiemetic prescribing practices using a computerized physician order entry system.
    Kadakia KC; Leal AD; Seisler DK; Qin R; Fee-Schroeder KC; Grendahl DC; Sorgatz KM; Loprinzi CL
    Support Care Cancer; 2014 Jan; 22(1):217-23. PubMed ID: 24026983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.
    Grunberg SM; Deuson RR; Mavros P; Geling O; Hansen M; Cruciani G; Daniele B; De Pouvourville G; Rubenstein EB; Daugaard G
    Cancer; 2004 May; 100(10):2261-8. PubMed ID: 15139073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey.
    Dielenseger P; Börjeson S; Vidall C; Young A; Jahn P
    Support Care Cancer; 2019 Nov; 27(11):4099-4106. PubMed ID: 30783815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting.
    Jordan K; Grothey A; Kegel T; Fibich C; Schöbert C
    Onkologie; 2005 Feb; 28(2):88-92. PubMed ID: 15662112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.